Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dousa

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2021
"One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis EnzymesDavid C Nguyen, Khalid M Dousa, Sebastian G Kurz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 30, 2025
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical TrialsKhalid M Dousa, Eunjeong Shin, Sebastian G Kurz, et al.
ACS Infectious Diseases|April 15, 2024
Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of <i>Mycobacterium tuberculosis</i>Mary Nantongo, David C Nguyen, Christopher R Bethel, et al.
Infection Control and Hospital Epidemiology|August 13, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid contamination of surfaces on a coronavirus disease 2019 (COVID-19) ward and intensive care unitSarah N Redmond, Khalid M Dousa, Lucas D Jones, et al.
Mbio|May 14, 2024
Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against <i>Mycobacterium abscessus</i>Khalid M Dousa, Eunjeong Shin, Sebastian G Kurz, et al.
Mbio|July 10, 2025
Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant <i>Mycobacterium tuberculosis</i>Mary Nantongo, David C Nguyen, Eunjeong Shin, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2020
Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane InhibitorsKhalid M Dousa, Sebastian G Kurz, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|June 17, 2025
Novel C5α-substituted carbapenems enhance <i>Mycobacterium abscessus</i> killing via selective target binding and reduced hydrolysis by Bla<sub>Mab</sub>Eunjeong Shin, Magdalena A Taracila, Pojun Quan, et al.
The Journal of Antimicrobial Chemotherapy|September 11, 2019
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from QatarMazen A Sid Ahmed, Hamad Abdel Hadi, Abubaker A I Hassan, et al.
Frontiers in Cardiovascular Medicine|February 15, 2021
Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-AnalysisMouhand F H Mohamed, Shaikha D Al-Shokri, Khaled M Shunnar, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2021
"One-Two Punch": Synergistic ß-Lactam Combinations for Mycobacterium abscessus and Target Redundancy in the Inhibition of Peptidoglycan Synthesis EnzymesDavid C Nguyen, Khalid M Dousa, Sebastian G Kurz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 30, 2025
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical TrialsKhalid M Dousa, Eunjeong Shin, Sebastian G Kurz, et al.
ACS Infectious Diseases|April 15, 2024
Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of <i>Mycobacterium tuberculosis</i>Mary Nantongo, David C Nguyen, Christopher R Bethel, et al.
Infection Control and Hospital Epidemiology|August 13, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid contamination of surfaces on a coronavirus disease 2019 (COVID-19) ward and intensive care unitSarah N Redmond, Khalid M Dousa, Lucas D Jones, et al.
Mbio|May 14, 2024
Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against <i>Mycobacterium abscessus</i>Khalid M Dousa, Eunjeong Shin, Sebastian G Kurz, et al.
Mbio|July 10, 2025
Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant <i>Mycobacterium tuberculosis</i>Mary Nantongo, David C Nguyen, Eunjeong Shin, et al.
Antimicrobial Agents and Chemotherapy|May 13, 2020
Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane InhibitorsKhalid M Dousa, Sebastian G Kurz, Magdalena A Taracila, et al.
Antimicrobial Agents and Chemotherapy|June 17, 2025
Novel C5α-substituted carbapenems enhance <i>Mycobacterium abscessus</i> killing via selective target binding and reduced hydrolysis by Bla<sub>Mab</sub>Eunjeong Shin, Magdalena A Taracila, Pojun Quan, et al.
The Journal of Antimicrobial Chemotherapy|September 11, 2019
Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from QatarMazen A Sid Ahmed, Hamad Abdel Hadi, Abubaker A I Hassan, et al.
Frontiers in Cardiovascular Medicine|February 15, 2021
Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-AnalysisMouhand F H Mohamed, Shaikha D Al-Shokri, Khaled M Shunnar, et al.
Pageof 4